HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Hüttner, S. Articles by Dugi, K. A. Search for Related Content PubMed PubMed Citation Articles by Hüttner, S. Articles by Dugi, K. A. Social Bookmarking                         What's this?

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of BI 1356, an Inhibitor of Dipeptidyl Peptidase 4, in Healthy Male Volunteers

From the departments of Clinical Research (Dr Hüttner), Drug Metabolism and Pharmacokinetics (Dr Graefe-Mody, Dr Withopf), Medical Data Services (Dr Ring), and Therapeutic Area Metabolic Diseases (Dr Dugi), Boehringer Ingelheim Pharma GmbH & Company KG, Biberach, Germany. Data from this study have previously been presented, in part, at the International Diabetes Federation World Diabetes Congress, Cape Town, December 2006, poster #821, and at the American Diabetes Association 67th Scientific Sessions, Chicago, Illinois, June 2007, poster #0586P.

This randomized, double-blind, parallel, placebo-controlled, single rising-dose study investigated the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of BI 1356 (once-daily, given orally) in healthy men. BI 1356 was well tolerated and safe up to and including a dose of 600 mg. The incidence of drug-related adverse events was equal in subjects receiving BI 1356 (30%) or placebo (31%). No clinically relevant deviations in laboratory or ECG parameters were reported. Exposure of BI 1356 increased less than proportionally from 2.5 mg to 5 mg, more than proportionally from 25 mg to 100 mg and approximately proportionally for doses from 100 mg to 600 mg. The geometric mean terminal half-life was up to 184 hours. Renal excretion was low. All doses of BI 1356 inhibited plasma dipeptidyl peptidase 4 activity. Single doses of 2.5 mg and 5 mg inhibited dipeptidyl peptidase 4 activity by 72.7% and 86.1% from baseline, respectively. The time to achieve maximum inhibition shifted with increasing doses from 3 hours (2.5 mg) to <0.7 hours (200 mg). Within the dose range tested, a direct pharmacokinetic/pharmacodynamic relationship was observed. The pharmacokinetic and pharmacodynamic profile results demonstrate the potency and full 24-hour duration of action of BI 1356. Based on an estimated therapeutic dose of 5 mg, the therapeutic window of BI 1356 is expected to be >100-fold.

Key Words: Pharmacokinetics • pharmacodynamics • type 2 diabetes • dipeptidyl peptidase 4 inhibitor • BI 1356

Address for reprints: Klaus A. Dugi, MD, Department of Therapeutic Area Metabolic Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, D-88397 Biberach, Germany; e-mail: klaus.dugi{at}boehringer-ingelheim.com.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?